Lab for Innovated Diagnosis and Experimental Therapeutics (LIDE) is a company for translational medicine. Founded in 2011 by overseas returnees Drs. Danyi Wen, Yizhun Zhu and few others, LIDE specializes in Oncology Translational Research and Immuno-oncology. With years of experience, LIDE has established a unique collection of more than five hundred patient derived xenograft (PDX) models, cultured more than 30 PDX matching primary tumor cell lines. In addition to the PDX model, LIDE is investigating into PDX-Hu model and mouse tumor isograft (MTI) model.
LIDE adopts the high international standard in daily operation. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class equipments. Company brings together first-class research and management teams, with solid scientific background and project management experience.
LIDE focuses on the frontier of international translational medical research, and vigorously promotes the development and application of translational medical research in China.
LIDE IO CRO service can provide in vitro functional evaluation on certain immune checkpoints related targets.
LIDE has established 600 + PDX models, including pancreatic , gastric, lung, liver, colon, CRC, ovarian, breast, esophageal, etc. We also evaluate drug efficacy on T790M model sensitive to AZD9291; and the model acquired AZD9291 drug resistance, and ALK model acquired drug resistance.
Protein Expression Visualization Services
Biochemistry & Molecular Biology Services
LIDE Path/BM team has developed methods for quick evaluation of the histopathology of the organs after drug treatment. Based on surgical separation and collection of organ tissues, timely fixation and embedding for FFPE block, we provide service for sectioning, H&E staining and microscopic evaluation of the drug related pathologic changes to support non-GLP toxicity studies for drug development.
IHC profiling and biomarker confirmation
LIDE has accumulated tremendous experience of IHC studies over the years of CRO studies, particularly worked on many biomarkers from oncology drug target related initiatives
Shanghai LIDE Biotech Co., Ltd. has not received any reviews.
Shanghai LIDE Biotech Co., Ltd. has not received any endorsements.